Inhibiting CD55 and CD59 for checkpoint inhibitor-resistant NSCLC

Inhibiting the complement suppressors CD55 and CD59, which are upregulated by EGFR signaling, could help treat NSCLC by increasing antitumor immune activity. In NSCLC patient tumor samples, expression of CD55 and CD59 was higher in tumor cells than adjacent normal tissues, and was inversely correlated with patient survival time and with tumor infiltration by CD8⁺ T cells and M1 macrophages. ...